Printer Friendly

Guidelines for the management of castrate-resistant prostate cancer.

Author(s): Fred Saad, MD, FRCSC, Sebastien J. Hotte, MD, FRCSC, FRCPC


Castrate-resistant prostate cancer (CRPC) is defined by disease progression despite androgen depletion therapy (ADT) and may present as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre-existing disease, and/or the appearance of new metastases.

Advanced prostate cancer has been known under a number of names over the years, including hormone-resistant prostate cancer (HRPC) and androgen-insensitive prostate cancer (AIPC). Most recently, the terms CRPC or castration recurrent prostate cancer were introduced with the realization that intracrine/paracrine androgen production plays is significant in the resistant of prostate cancer cells to testosterone suppression therapy.[sup.1] In their second publication, the Prostate Cancer Working Group (PCWG2) defined CRPC as a continuum on the basis of whether metastases are detectable (clinically or by imaging) and whether the serum testosterone is in the castrate range by a surgical orchidectomy or medical therapy.[sup.2] This continuum creates a clinical-states model where patients can be classified. The rising PSA states (castrate and noncastrate) signify that no detectable (measurable or non-measurable) disease has ever been found. The clinical metastases states (castrate and noncastrate) signify that disease was detectable at some point in the past, regardless of whether it is detectable now.

Prognosis is associated with several factors, including performance status, presence of bone pain, extent of disease on bone scan and serum alkaline phosphatase levels. Bone metastases will occur in 90% of men with CRPC and can produce significant morbidity, including pain, pathologic fractures, spinal cord compression and bone marrow failure. Paraneoplastic effects are also common, including anemia, weight loss, fatigue, hypercoagulability and increased susceptibility to infection.

CRPC presents a spectrum of disease ranging from patients without metastases or symptoms with rising PSA levels despite ADT, to patients with metastases and significant debilitation due to cancer symptoms.

Management of CRPC

Secondary hormonal manipulations

In patients who develop CRPC and who are relatively asymptomatic, secondary hormonal treatments may be attempted. Level 2 Evidence, Grade C recommendation

To date, no study of secondary hormone treatment has demonstrated benefits in terms of survival, but most trials have been smaller and heavily confounded by the future treatments used. In patients treated with luteinizing-hormone-releasing hormone agonist monotherapy or who have had an orchidectomy, total androgen blockade (TAB) with testosterone antagonists, such as bicalutamide, can offer PSA responses in 30% to 35% of patients. For patients who progress on ADT without evidence of distant metastases, it is suggested to screen them for bone metastases and to monitor them for visceral metastases/progression with abdomen and chest imaging. Exact timing of imaging may be modulated using PSA doubling time. Imaging techniques most commonly used include nuclear bone scans and abdominal computed tomography and chest X-ray. The role of magnetic resonance imaging and positron emission tomography is still unclear.

For patients who have undergone TAB, the antiandrogen could be discontinued to exclude an antiandrogen withdrawal response (AAWD). The introduction or changes of an AA or the use of ketoconazole has been reported to have transient PSA reductions in about 30% of patients.[sup.3] Level 3 Evidence, Grade C recommendation

Because the androgen receptor remains active in most patients who have developed castration resistant disease, it is recommended by groups, such as ASCO (American Society of Clinical Oncology), NCCN (National Comprehensive Cancer Network), CCO (Cancer Care Ontario) and others, that ADT should be continued. Level 3 Evidence, Grade C recommendation

Systemic corticosteroid therapy

Corticosteroid therapy with low-dose prednisone or dexa-methasone may also offer improvements in PSA values and/or palliative outcomes in up to 30% of patients in both symptomatic and asymptomatic men. Steroids may also exert an anti-neoplastic effect on prostate cancer.[sup.4,5] Level 3 Evidence, Grade C recommendation

First-line systemic chemotherapy

Currently, only patients with CRPC who have detectable macroscopic metastatic disease should be considered for systemic chemotherapy outside of a clinical trial. Patients with advanced prostate cancer should be referred early for possible chemotherapy and should receive multidisciplinary care to maximize survival and optimize quality of life. Because any treatment for advanced disease remains palliative, patients with advanced prostate cancer should be encouraged to participate in clinical trials.

Docetaxel and prednisone in combination are currently considered the standard of care for men with CRPC with detectable metastatic disease. This is based largely on the simultaneous publication of two large randomized controlled trials comparing this combination to the previously established standard of mitoxantrone and prednisone.[sup.6,7] Level 1 Evidence, Grade A recommendation

Docetaxel is a taxane drug that induces polymerization of microtubules and phosphorylation of bcl-2 protein. Tannock and colleagues randomized 1006 patients to one of three treatment arms: docetaxel (75 mg/m[sup.2] intravenously every 3 weeks), docetaxel (30 mg/m[sup.2] 5 times weekly for 5 of 6 weeks), or control therapy with mitoxantrone.[sup.6] All patients also received prednisone 5 mg po BID. Petrylak and colleagues reported on 666 eligible patients randomized to docetaxel and estramustine (EMP) or mitoxantrone-prednisone.[sup.7] In addition to dexamethasone premedication, patients in the docetaxel arm also received warfarin and/or acetylsalicylic acid (ASA) as thrombosis prophylaxis during the course of the trial. Men in both trials had clinical evidence of metastases with or without symptoms and had undergone AAWD. Overall survival was the primary endpoint in both trials.

Tannock and colleagues reported improved survival with docetaxel (every 3 weeks) compared with mitoxantrone-prednisone (median survival, 18.9 vs. 16.5 months; hazard ratio [HR] = 0.76 [95% confidence interval (CI), 0.62-0.94], two-sided p = 0.009).[sup.7] No overall survival benefit was observed with docetaxel given on a weekly schedule (HR = 0.91, [95% CI, 0.75-1.11], two-sided p = 0.36). Petrylak and colleagues reported longer survival time with docetaxel-EMP combination chemotherapy compared with mitoxantrone (median survival, 17.5 vs. 15.6 months; HR = 0.80 [95% CI, 0.67-0.97], two-sided p = 0.02).[sup.6] This trial also reported a median progression-free interval of 6.3 versus 3.2 months (HR = 0.73 [95% CI, 0.63-0.86], two-sided p < 0.0001) favouring docetaxel-EMP compared with mitoxantrone. Pain response was assessed in both trials. Significantly more patients treated with docetaxel (every 3 weeks) achieved a pain response compared with patients receiving mitoxantrone (35% vs. 22%, p = 0.01). A trend towards improved pain response was observed with weekly docetaxel versus mitoxantrone (31% vs. 22%, p = 0.08). Quality of life response, defined as a sustained 16-point or greater improvement from baseline on two consecutive measurements, was higher with docetaxel given every 3 weeks (22% vs. 13%, p = 0.009) or weekly (23% vs. 13%, p = 0.005) compared with mitoxantrone. Petrylak and colleagues reported no difference in patient reported pain relief between arms in their trial and did not assess quality of life.[sup.6] In both trials, PSA response rates were also statistically significantly higher with docetaxel compared to mitoxantrone. Twenty-seven percent (n = 412) and 29% (n = 196) of patients in the 2 trials had measurable disease. Objective response rates for docetaxel (every 3 weeks) and mitoxantrone were 12% versus 7%, respectively. Petrylak and colleagues reported objective response rates of 17% and 11% favouring docetaxel-EMP compared with mitoxantrone. The differences in objective response rates between arms were not statistically significant in either trial.

Based on the results of these 2 randomized controlled trials, it is now recommended that for men with clinical or biochemical evidence of progression and evidence of metastases, treatment with docetaxel 75 mg/m[sup.2] administered intravenously every 3 weeks with 5 mg oral prednisone twice daily should be offered to improve overall survival, disease control, symptom palliation and quality of life.[sup.8,9] Level 1 Evidence, Grade A recommendation

Although patients in the 2 pivotal trials received up to 10 cycles of treatment if no progression and no prohibitive toxicities were noted, the duration of therapy should be based on the assessment of benefit and toxicities. A rising PSA should not be the used as the sole criteria for the progression; the assessment of response should incorporate clinical and radiographic criteria. Alternative therapies that have not demonstrated improvement in overall survival, but can provide disease control, palliation and improve quality of life include weekly docetaxel plus prednisone and mitoxantrone plus prednisone.[sup.10] Level 2 Evidence, Grade B recommendation

The timing of docetaxel therapy in patients with evidence of metastases but without symptoms should be discussed with the patient; therapy should be individualized based on the patient's clinical status and preferences. Level 3 Evidence, Grade C recommendation

The use of estramustine in combination with other cytotoxic agents is not recommended due to the increased risk of clinically important toxicities without evidence of improved survival or palliation. Level 2 Evidence, Grade C recommendation

For patients who do not respond to first-line ADT or progress clinically or radiologically without significant PSA elevations may have neuroendocrine differentiation. The NCCN guideline suggests that a biopsy of accessible lesions should be considered to identify those patients, who should then be treated with combination chemotherapy, such as cisplatin/etoposide or carboplatin/etoposide. Level 3 Evidence, Grade C recommendation

Second-line systemic chemotherapy

Unfortunately, no treatment has been shown to improve survival or quality of life in patients who have progressed on docetaxel-based chemotherapy or soon after this therapy; participation in a clinical trial should be encouraged.[sup.11]-[sup.15]

For now, mitoxantrone is considered the de facto second-line chemotherapy, but has limited activity and increased toxicity in this setting. Level 4 Evidence, Grade D recommendation

For patients who have not demonstrated definitive evidence of resistance to docetaxel, retreatment with docetaxel agent can be considered.[sup.16]-[sup.19] Level 3 Evidence, Grade C recommendation

Recently reported unpublished results using cabazitaxel compared to mitoxantrone in patients previously treated with docetaxel have shown a statistically significant survival advantage.[sup.20] This randomized, placebo-controlled trial recruited 755 docetaxel-pretreated CRPC patients. Overall survival was the primary endpoint of the study. Patients were randomized to receive prednisone 10 mg/day with 3-weekly mitoxantrone 12 mg/m[sup.2] or cabazitaxel 25 mg/m[sup.2]. An advantage in survival emerged in favour of the cabazitaxel group, with a median survival of 15.1 months compared with 12.7 months in the mitoxantrone group (HR 0.70; 95% CI 0.59, 0.83; p < 0.0001). In light of these positive results, cabazitaxel may soon play a prominent role as second-line treatment in CRPC patients.

Palliative radiation

Bone metastases from prostate cancer are often radiosensitive and most men will experience partial or complete pain relief from radiation to a specific lesion.[sup.21] Studies have shown that a single fraction is as effective as 5 fractions in providing palliation. However, more patients require retreatment for pain recurrence. Level 2 Evidence, Grade B recommendation

In some patients with diffuse bone pain, radio-isotopes can be considered. Because of their potential for marrow suppression, adequate blood counts are required to initiate treatment. The two main radio-isotopes used are strontium and samarium. The main advantage of samarium over strontium is its shorter scatter which causes less marrow suppression. Level 3 Evidence, Grade C recommendation

Bone-targeted therapy

Bone loss associated with ADT has been shown to increase the risk of fracture.[sup.22]-[sup.24] Moreover, about 90% of patients with metastatic CRPC will develop bone metastases, which cause local decreases in bone integrity. Patients are at significant risk of developing skeletal complications, including pathological fractures, debilitating bone pain and spinal cord compression. The patient's quality of life is affected by these complications.[sup.25]

In men with CRPC and bone metastases, zoledronic acid (4 mg intravenously) every 3 to 4 weeks is recommended to prevent disease-related skeletal complications, including pathological fractures, spinal cord compression, surgery or radiation therapy to bone.[sup.26,27] Level 1 Evidence, Grade A recommendation

Other bisphosphonates are not known to be effective for the prevention of disease-related skeletal complications. The infusion time for zoledronic acid should be no less than 15 minutes to reduce the risk of affecting renal function. Serum creatinine monitoring is suggested prior to each dose. Results from the randomized study showed fewer men receiving zoledronic acid had skeletal-related events while on study than men in the placebo group (38% vs. 49% p = 0.02).[sup.26] Zoledronic acid also increased the median time to first skeletal-related event (488 days vs. 321 days, p = 0.01). There was an overall 36% reduction in the rate of skeletal-related events in treated patients. Zoledronic acid should be initiated at reduced doses in men with impaired renal function (estimated creatinine clearance 30 to 60 mL/min). Treatment is not recommended for men with baseline creatinine clearance <30 mL/min. Based on the recommendations for other settings, bisphosphonate therapy for bone metastases should be continued for as long as clinically beneficial. The optimal duration of zoledronic acid in men with CRPC and bone metastases is undefined, however efficacy and safety for up to 24 months has been shown in the randomized controlled trial.[sup.26] Zoledronic acid and other bisphosphonates are associated with an increased risk of osteonecrosis of the jaw (ONJ). Most, but not all, patients who develop ONJ have pre-existing dental problems.

Good oral hygiene, baseline dental evaluation for high-risk individuals and avoidance of invasive dental surgery during therapy are recommended to reduce risk of ONJ[sup.28]-[sup.30] (Level 3 Evidence, Grade C recommendation). Zoledronic acid has been used safely with a variety of cytotoxic chemotherapies in clinical trials.[sup.31] Adverse events reported during bisphosphonate treatment did not appear to increase with concomitant chemotherapy.

Based on the available evidence, several guidelines (including those of the NCCN, the European Association of Urology and the International Consultation on Urological Diseases) recommend that bisphosphonates be used to preserve bone health and to prevent skeletal complications in patients with bone metastases from CRPC, whether asymptomatic or symptomatic. Other bone-targeted agents include the RANK ligand inhibitor denosumab, which has been shown to be effective in preventing bone loss and new vertebral fractures due to ADT.[sup.32,33] In a recent randomized controlled trial, denosumab has shown its effectiveness in delaying and reducing skeletal-related events when compared to zoledronic acid and may soon become another option for patients with metastatic CRPC.[sup.34]

Clinical trials and future directions

Men with CRPC are living longer and with improved quality of life, but most patients, if not all, eventually succumb to their disease and better treatments are required. Several new agents are being studied in a pre-chemotherapy setting, in combination with docetaxel as well as in the post-docetaxel setting. It is hoped that the near future will lead to more therapeutic options for patients with CRPC. Because CRPC remains an incurable and ultimately fatal illness, participation in clinical trials at all stages of the disease remains paramount.


Advanced CRPC is a multifaceted problem and needs a multidisciplinary approach. Maintenance of quality of life and supportive care remains the priority. For patients with metastatic CRPC, docetaxel-based chemotherapy is recommended to improve survival and quality of life. Zoledronic acid is also recommended to reduce the risk of bone complications. There are other treatments presently under investigation that may soon add to the therapeutic options available. It is necessary to build on what is presently available to further improve the outcome in these poor-prognosis patients.

Additional notes: MEDLINE search of the English language and conference proceedings were used to produce the present document. Levels of evidence and grades of recommendation employing the International Consultation on Urologic Disease (ICUD)/WHO modified Oxford Center for Evidence-Based Medicine grading system.

Competing interests: Dr. Saad and Dr. Hotte serve as advisors and have conducted research with Novartis, sanofi aventis and Amgen. No financial support was obtained for the work in preparing this document.

This paper has been peer-reviewed.


1.. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67:5033-41.

2.. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.

3.. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-33.

4.. Storlie JA, Buckner JC, Wiseman GA, et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995;76:96-100.

5.. Heng DY, Chi KN. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer. Can J Urol 2006;13:3335-9.

6.. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.

7.. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.

8.. Winquist E, Waldron T, Berry S, et al. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. BMC Cancer 2006;6:112-130.

9.. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Fort Washington, PA: NCCN; Accessed October 18, 2010.

10.. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996;14:1756-64.

11.. Michels J, Montemurro T, Murray N, et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 2006;106:1041-6.

12.. Oh WK, Manola J, Babcic V, et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006;67:1235-40.

13.. Berthold DR, Pond G, De Wit R, et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19:1749-53.

14.. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110:556-63.

15.. Berger ER, Ciuleanu T, Hart L, et al. Results of a randomized phase II study of irofulven in hormone-refractory prostate cancer patients that have failed first-line docetaxel treatment [abstract 5068]. J Clin Oncol 2007;2518S.

16.. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008;112:326-30.

17.. Jankovic B, Beardsley E, Chi KN. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: a population based analysis [abstract 196].2008 ASCO Genitourinary SymposiumFebruary 14-16, 2008San Francisco, CA.

18.. Ansari J, Hussain SA, Zarkar A, et al. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 2008:891-6.

19.. Eymard J, Oudard S, Gravis G, et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU IntEpub 2010 Mar 9.

20.. Sartor AO, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC) [abstract 9].Presented at: 2010 ASCO Genitourinary Cancers SymposiumMarch 5-7, 2010San Francisco, CA.

21.. Wu JS, Wong RK, Lloyd NS, et al. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases - an evidence-based practice guideline. BMC Cancer 2004;4:71.

22.. Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-9.

23.. Preston DM, Torrens JI, Harding P, et al. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 2002;5:304-10.

24.. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64.

25.. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84.

26.. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.

27.. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals Oncol 2008;19:420-32.

28.. Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008;14:277-85.

29.. Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29:1548-58.

30.. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14.

31.. Ullen A, Lennartsson L, Harmenberg U, et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005;44:644-50.

32.. Saad F, Markus R, Goessl C. Targeting the receptor activator of nuclear factor-kB (RANK) ligand in prostate cancer bone metastases. BJU Int 2007;101:1071-5.

33.. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55.

34.. Fizazi K, Carducci M, Smith M, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with castration resistant prostate cancer [abstract LBA4507]. J Clin Oncol 2010;28:18s.


Fig. 1.: Proposed approach for patients with castrate resistant prostate cancer with presently available agents. PSA = prostate-specific antigen; PSADT = PSA doubling time; CRPC = castrate-resistant prostate cancer. [Figure omitted]

Author Affiliation(s):

[1] Director of Urologic Oncology Centre Hospitalier de l'Universite de Montreal, Montreal, QC;

[2] Department of Oncology - Division of Medical Oncology, Associate Professor, McMaster University, Hamilton, ON

Correspondence: Dr. Fred Saad, Universite de Montreal, Directeur, Urologie-Oncologie, CHUM, 1560 Sherbrooke E., Montreal, QC H2L 4M1;
COPYRIGHT 2010 Canadian Urological Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CUA Guideline
Author:Saad, Fred; Hotte, Sebastien J.
Publication:Canadian Urological Association Journal (CUAJ)
Geographic Code:1CANA
Date:Dec 1, 2010
Previous Article:Evaluation and medical management of the kidney stone patient.
Next Article:Peer-reviewed publications by CUA members: then and now.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters